Sanofi (NYSE:SNY) announced today that it plans to invest approximately $476.3 million (€400 million) per year on mRNA vaccine development. Paris-based Sanofi’s intends for its annual investment to go toward a first-of-its-kind vaccine “mRNA Center of Excellence” to accelerate the development and delivery of next-generation vaccines. Get the full story at our sister site, Drug […]
coronavirus
Here at MassDevice — medtech's online business journal — we're covering news about the coronavirus (COVID-19) pandemic daily. Here is the latest about coronavirus and the medical device industry, regulatory changes related to the pandemic, new tests for the virus, vaccine development, and much more.
Pfizer/BioNTech and Moderna vaccines appear to have a durable immune response
A new study shows that the Pfizer and Moderna COVID-19 vaccines create an immune response that may protect recipients for years. The study, published in Nature, revealed that those who received the two-dose mRNA vaccines developed by Pfizer/BioNTech and Moderna could provide immunity for years or even a lifetime in those who were infected with COVID-19 […]
Abbott wins CE mark to sell Panbio COVID-19 antigen test over the counter
Abbott (NYSE:ABT) announced today that it received CE mark approval to market the Panbio COVID-19 test for over-the-counter use. European approval covers the direct-to-consumer sale of the Panbio COVID-19 antigen self-test for detecting the SARS-CoV-2 virus in adults and children both with or without symptoms. Abbott Park, Ill.-based Abbott’s Panbio antigen self-test uses a minimally […]
MedTech 100 roundup: Nearing new highs once again
Having hit a downturn as the summer neared, the medtech industry is now consistently on the rise as June comes to a close. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the week (June 25) at 113.42 points, producing a 2.5% rise from the 110.64-point mark set […]
Roche wins EUA for intravenous tocilizumab in treating COVID-19
Roche announced today that it received FDA emergency use authorization (EUA) for intravenous Actemra/RoActemra in treating COVID-19. Basel, Switzerland-based Roche’s Actemra/RoActemra (tocilizumab) drug received authorization to treat COVID-19 in hospitalized adults and pediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation or […]
White House allocates 55M COVID-19 vaccine doses for global distribution
The Biden-Harris administration today announced a global distribution list for 55 million doses of America’s COVID-19 vaccine supply. Biden pledged to allocate 80 million doses of the COVID-19 vaccine supply belonging to the U.S. by the end of June to aid the global fight against the pandemic. Earlier this month, the administration announced the plan […]
Biden administration invests $3B to accelerate development of next-gen COVID-19 treatments
President Joe Biden’s administration will spend $3 billion in American Rescue Plan money to accelerate the discovery, development and manufacturing of antiviral medicines against COVID-19, HHS announced today. Not only will the Antiviral Program for Pandemics seek to boost the availability of medicines to prevent serious COVID-19 illness and save lives, but it will pursue […]
CureVac’s interim vaccine efficacy is 47% in Phase 2b/3 study
Germany-based CureVac (NSDQ:CVAC) announced that its mRNA vaccine was 47% effective against COVID-19 in a second interim analysis of a pivotal study involving approximately 40,000 participants in 10 countries. The rise of COVID-19 variants played a role in the disappointing results. At least 13 COVID-19 variants were present in the study population who contracted the […]
U.S. government buys 200M more doses of Moderna’s COVID-19 vaccine
Moderna (NSDQ:MRNA) announced today that the U.S. government purchased an additional 200 million doses of its COVID-19 vaccine. The government’s purchase agreement with Moderna also includes the option to purchase other COVID-19 vaccine candidates to come out of the company’s pipeline. Get the full story at our sister site, Pharmaceutical Processing World.
Novavax’s COVID-19 vaccine demonstrates 90% efficacy
Novavax (NSDQ:NVAX) announced today that its COVID-19 vaccine demonstrated 90.4% efficacy in protecting against COVID-19. Gaithersburg, Md.–based Novavax’s recombinant nanoparticle protein-based COVID-19 vaccine demonstrated 100% protection against moderate and severe disease, with 90.4% efficacy overall as it met the primary endpoint in the Prevent-19 pivotal Phase 3 trial. Get the full story at our sister site, […]
J&J must reportedly throw out 60M COVID-19 vaccine doses from Emergent plant
Another large amount of doses of Johnson & Johnson’s COVID-19 vaccine produced at an embattled manufacturing plant reportedly have to be thrown out. The New York Times reported that the FDA told J&J that about 60 million doses of the single-dose vaccine produced at Emergent BioSolutions’ Baltimore plant can’t be used because of possible contamination. Get the full […]